Publications on Preclinical Models
of Parkinson’s and Alzheimer’s Disease
- Fares MB, Jagannath S, Lashuel HA. Reverse engineering Lewy bodies: how far have we come and how far can we go? Nat Rev Neurosci. 2021 Feb;22(2):111-131. doi: 10.1038/s41583-020-00416-6. Epub 2021 Jan 11.
- Mahul-Mellier AL, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, Leleu M, Knott GW, Lashuel HA. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proceedings of the National Academy of Sciences. 2020 Mar 3;117(9):4971-4982. doi: 10.1073/pnas.1913904117. Epub 2020 Feb 19. PMID: 32075919; PMCID: PMC7060668.
- Fares MB, Maco B, Oueslati A, Rockenstein E, Ninkina N, Buchman V, Masliah E, Lashuel HA. Induction of de novo α-Synuclein fibrillization in a novel neuronal model for Parkinson’s disease. Proceedings of the National Academy of Sciences. 2016, 16;113(7): E912-21.
- Mahul-Mellier A, Vercruysse F, Maco B, Ait-Bouziad N, De Roo M, Muller D and Lashuel HA. Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell death. Cell Death and Differentiation. 2015, (12):2107-22.
- Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, Muhs A, Lashuel HA. Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species. Journal of Biological Chemistry. 2011, 286(10):8585-96.